INTERGROWTH-21st is a clinical tool for healthcare providers to assess fetal and preterm infant growth, available as a free utility on iOS.
The App DNA
What makes this app unique?
Clinicians need standardized, evidence-based tools to track preterm development until 64 weeks post-menstrual age, where WHO standards begin.
For Healthcare providers, medical researchers, and clinicians managing maternal and neonatal care.
What does it look like?
Key features
Calculates and plots size at birth and postnatal growth for preterm infants up to 64 weeks post-menstrual age.
Provides prescriptive, international standards for fetal growth and newborn size as adjuncts to WHO charts.
How much does it cost?
The app operates as a free, non-commercial tool provided by the University of Oxford to support global clinical standards.
Velocity
Maintenance developmentnew contentUX improvementsShow more...
INTERGROWTH-21st is currently in a maintenance phase, having shipped only one release in the last 147 days. The latest version focused on expanding growth standards and updating store assets, but there has been no significant development activity since. The current cadence of approximately 0.05 releases per week indicates a focus on long-term stability rather than active feature iteration.
Who built it?
User Sentiment
What do users think recently?
How are ratings & reviews evolving?
Not enough recent reviews to extract reliable themes yet.
Read the full review analysisCompetition
Competitive landscape for INTERGROWTH-21st
How's the Health & Fitness market?
INTERGROWTH-21st serves a specialized clinical segment, functioning as a non-commercial utility rather than a consumer-facing app. Its position relies on the University of Oxford's research authority rather than market-driven growth metrics.
Read the market outlookThe rivals identified
Unlock the deeper market read.
Access the full report for freeThe Analyst's Read
Key takeaways for INTERGROWTH-21st
Where is it heading?
The clinical utility market for neonatal growth remains stable, with INTERGROWTH-21st serving as a niche, research-backed reference. The lack of active feature expansion suggests the app will remain a static tool, which is sufficient for its current purpose but leaves it vulnerable to future updates in international growth standards.
- The ~21-week update cadence confirms a maintenance-only lifecycle, which limits the app's ability to adapt to changing clinical standards.
The SWOT
- Clinical standards integration provides a defensible barrier against generic health trackers
- Localized clinical adoption in regions lacking standardized neonatal tools
Next best moves
Audit clinical feedback channels because the ~21-week update cadence suggests a disconnect from user needs → improve utility relevance
The counter-intuitive read
The app's lack of commercial monetization is its primary competitive advantage…
Read the full takeSince the last report: The app's positioning shifted toward a non-commercial, foundational utility model, while the underlying product remains in a static maintenance state. No functional changes or feature updates occurred during this period.
Bottom line
INTERGROWTH-21st maintains its utility as a specialized clinical reference, but the dormant release cadence risks obsolescence as global standards evolve. Prioritizing a feedback loop with clinical users would ensure the tool remains aligned with current neonatal care requirements.
Unlock 1 critical friction, 1 market threat and the analyst’s take.
Access the full report for freeSources
Report last updated